Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice
- PMID: 17636457
- DOI: 10.1007/s10928-007-9065-1
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice
Abstract
Although it is known that FcRn, the neonatal Fc-receptor, functions to protect immune gamma globulin (IgG) from elimination, the influence of FcRn on the tissue distribution of IgG has not been quantified. In the present work, a physiologically-based pharmacokinetic (PBPK) model has been developed to characterize and predict IgG disposition in plasma and in tissues. The model includes nine major compartments, connected in an anatomical manner, to represent tissues known to play a significant role in IgG disposition. Each tissue compartment was subdivided into vascular, endosomal and interstitial spaces. IgG transport between the blood and interstitial compartments may proceed by convection through paracellular pores in the vascular endothelium, or via FcRn-mediated transcytosis across vascular endosomal cells. The model was utilized to characterize plasma concentration-time data for 7E3, a monoclonal antiplatelet IgG1 antibody, in control and FcRn-knockout (KO) mice. These data showed that high dose intravenous immunoglobulin (IVIG), 1g/kg, increased 7E3 clearance in control mice from 5.2 +/- 0.3 to 14.4 +/- 1.4 ml/d/kg; however, IVIG failed to increase the clearance of 7E3 in KO mice (72.5 +/- 4.0 vs. 61.0 +/- 3.6 ml/d/kg). Based on model fitting to the 7E3 plasma concentration data, simulations were conducted to predict tissue concentrations of IgG in control and in KO mice, and the predictions were then tested by assessing 7E3 tissue distribution in KO mice and control mice. 7E3 was radiolabeled with Iodine-125 using chloramine T method, and (125)I-7E3 IgG was administered at a dose of 8 mg/kg to control and KO mice. At various time points, sub-groups of 3 mice were sacrificed, blood and tissue samples were collected, and radioactivity assessed by gamma counting. PBPK model performance was assessed by comparing model predictions with the observed data. The model accurately predicted 7E3 tissue concentrations, with mean predicted vs. observed AUC ratios of 1.04 +/- 0.2 and 0.86 +/- 0.3 in control and FcRn-KO mice. The PBPK model, which incorporates the influence of FcRn on IgG clearance and disposition, was found to provide accurate predictions of IgG tissue kinetics in control and FcRn-knockout mice.
Similar articles
-
Pharmacokinetic/pharmacodynamic modeling of the effects of intravenous immunoglobulin on the disposition of antiplatelet antibodies in a rat model of immune thrombocytopenia.J Pharm Sci. 2003 Jun;92(6):1206-15. doi: 10.1002/jps.10364. J Pharm Sci. 2003. PMID: 12761810
-
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):67-86. doi: 10.1007/s10928-011-9232-2. Epub 2011 Dec 6. J Pharmacokinet Pharmacodyn. 2012. PMID: 22143261
-
The effect of the neonatal Fc receptor on human IgG biodistribution in mice.MAbs. 2014 Mar-Apr;6(2):502-8. doi: 10.4161/mabs.27765. Epub 2014 Jan 9. MAbs. 2014. PMID: 24492305 Free PMC article.
-
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2. Mol Immunol. 2013. PMID: 23917469 Review.
-
Pharmacokinetic models for FcRn-mediated IgG disposition.J Biomed Biotechnol. 2012;2012:282989. doi: 10.1155/2012/282989. Epub 2012 May 14. J Biomed Biotechnol. 2012. PMID: 22665983 Free PMC article. Review.
Cited by
-
In Translation: FcRn across the Therapeutic Spectrum.Int J Mol Sci. 2021 Mar 17;22(6):3048. doi: 10.3390/ijms22063048. Int J Mol Sci. 2021. PMID: 33802650 Free PMC article. Review.
-
Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley Rats.Pharm Res. 2022 Mar;39(3):481-496. doi: 10.1007/s11095-022-03204-2. Epub 2022 Mar 4. Pharm Res. 2022. PMID: 35246757
-
Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease.AAPS J. 2010 Mar;12(1):33-43. doi: 10.1208/s12248-009-9157-5. Epub 2009 Nov 19. AAPS J. 2010. PMID: 19924542 Free PMC article. Review.
-
Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency.CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1316-1327. doi: 10.1002/psp4.12847. Epub 2022 Aug 8. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 35860862 Free PMC article.
-
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.Antibodies (Basel). 2019 Jan 1;8(1):3. doi: 10.3390/antib8010003. Antibodies (Basel). 2019. PMID: 31544809 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials